Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Personality Disorder, Schizoid

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Personality Disorder, Schizoid in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abi-Dargham, A; Cooper, T; Kegeles, LS; Koenigsberg, HW; Laruelle, M; Martinez, D; Mawlawi, O; Mitropoulou, V; O'Flynn, K; Siever, LJ; Van Heertum, R; Zea-Ponce, Y1

Other Studies

1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Personality Disorder, Schizoid

ArticleYear
Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Biological psychiatry, 2004, May-15, Volume: 55, Issue:10

    Topics: Adult; Amphetamine; Analysis of Variance; Benzamides; Case-Control Studies; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Schizoid Personality Disorder; Tomography, Emission-Computed, Single-Photon

2004